Medicines labeled for the same conditions
Alternatives to entrectinib
26 other medicines are given the same way (oral) and in the same FDA class as entrectinib or labeled mainly for the same use (lung cancer); the others include 18 kinase inhibitors and 1 topoisomerase inhibitor (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as entrectinib?
The first 24 of the 26, the same class first. Lung cancer lists all 55 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Entrectinib | this medicine | none listed | n/a | No | No current entry |
| Erlotinibkinase inhibitor | Lung cancer | 10 labelers | n/a | No | No current entry |
| Afatinibkinase inhibitor | Lung cancer | 1 labeler | n/a | No | No current entry |
| Selpercatinibkinase inhibitor | Lung cancer | none listed | n/a | No | No current entry |
| Crizotinibkinase inhibitor | Lung cancer | none listed | n/a | No | No current entry |
| Gefitinibkinase inhibitor | Lung cancer | 4 labelers | n/a | No | No current entry |
| Brigatinibkinase inhibitor | Lung cancer | none listed | n/a | No | No current entry |
| Dabrafenibkinase inhibitor | Lung cancer | none listed | n/a | No | No current entry |
| Dacomitinib | Lung cancer | none listed | n/a | No | A presentation being discontinued |
| Lorlatinibkinase inhibitor | Lung cancer | none listed | n/a | No | A presentation being discontinued |
| Sotorasib | Lung cancer | none listed | n/a | No | No current entry |
| Trametinibkinase inhibitor | Lung cancer | none listed | n/a | No | No current entry |
| Capmatinibkinase inhibitor | Lung cancer | none listed | n/a | No | No current entry |
| Ensartinib | Lung cancer | none listed | n/a | No | No current entry |
| Lazertinibkinase inhibitor | Lung cancer | none listed | n/a | No | No current entry |
| Repotrectinibkinase inhibitor | Lung cancer | none listed | n/a | No | No current entry |
| Topotecantopoisomerase inhibitor | Lung cancer | none listed | n/a | Yes | No current entry |
| Zidesamtinib | Lung cancer | none listed | n/a | No | No current entry |
| Adagrasib | Lung cancer | none listed | n/a | No | No current entry |
| Alectinibkinase inhibitor | Lung cancer | none listed | n/a | No | No current entry |
| Binimetinib | Lung cancer | none listed | n/a | No | No current entry |
| Ceritinibkinase inhibitor | Lung cancer | none listed | n/a | No | No current entry |
| Pralsetinibkinase inhibitor | Lung cancer | none listed | n/a | Yes | No current entry |
| Sevabertinib | Lung cancer | none listed | n/a | No | No current entry |
| Taletrectinib adipatekinase inhibitor | Lung cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Entrectinib: the full record
- label, generics, price, shortages, recalls